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Myoﬁbroblast, cell differentiationCardiac ﬁbroblast differentiation tomyoﬁbroblast is a crucial process in the development of cardiac ﬁbrosis and is
tightly dependent on transforming growth factor beta-1 (TGF-β1). The transcription factor forkhead box O1
(FoxO1) regulates many cell functions, including cell death by apoptosis, proliferation, and differentiation.
However, several aspects of this process remain unclear, including the role of FoxO1 in cardiac ﬁbroblast
differentiation and the regulation of FoxO1 by TGF-β1. Here, we report that TGF-β1 stimulates FoxO1 expression,
promoting its dephosphorylation, nuclear localization and transcriptional activity in cultured cardiac ﬁbroblasts.
TGF-β1 also increases differentiation markers such as α-smooth muscle actin, connective tissue growth factor,
and pro-collagen I, whereas it decreases cardiac ﬁbroblast proliferation triggered by fetal bovine serum. TGF-
β1 also increases levels of p21waf/cip-cycle inhibiting factor protein, a cytostatic factor promoting cell cycle ar-
rest and cardiac ﬁbroblast differentiation. In addition, TGF-β1 increases cardiac ﬁbroblast contractile capacity
as assessed by collagen gel contraction assay. The effect of TGF-β1 on cardiac ﬁbroblast differentiation was
prevented by FoxO1 down-regulation and enhanced by FoxO1 overexpression. Thus, our ﬁndings reveal that
FoxO1 is regulated by TGF-β1 and plays a critical role in cardiac ﬁbroblast differentiation. We propose that
FoxO1 is an attractive new target for anti-ﬁbrotic therapy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus, hypertension, and myocardial infarction promote
the development of cardiac ﬁbrosis [1–6]. In these pathological con-
ditions, normally quiescent cardiac ﬁbroblasts (CFs) are activated,
differentiating to cardiac myoﬁbroblasts (CMFs). The physiological
role of CMF has been associated with tissue healing [7]. However,
in pathological conditions CMFs secrete extracellular matrix protein
(mainly collagen type I), which favors progressive cardiac ﬁbrosis in-
creasingmyocardial stiffness leading to diastolic dysfunction anddecreas-
ing myocardial function [8]. In hypertensive rats, thiazolidinediones,yoﬁbroblasts; FBS, fetal bovine
α-smooth muscle actin; FoxO,
tor; p21(WAF1/CIP1), p21-cy-
ndent kinase inhibitor.
ic Diseases (ACCDiS), Faculty of
e, University of Chile, 8380492
gadiaz@ciq.uchile.clrelaxin, and antioxidants reduce the presence of positive alpha-smooth
muscle actin (α-SMA) cells, which is a marker of CF to CMF differentia-
tion, different to those founded in vascular smooth muscle cells own to
blood vessels; this decrease correlateswith reduced cardiac tissue ﬁbrosis
and improvedmyocardial function [8–10]. This observation highlights the
importance of CF differentiation into CMF in cardiac ﬁbrosis.
The cytokine TGF-β1 plays a crucial role in the development of ﬁbro-
sis, by inducing the differentiation of CF into CMF [11,12], whereas in
rats withmyocardial infarction, reduced levels of this cytokine are relat-
ed to decrease α-SMA positive cells and collagen I expression which
correlates with ameliorate cardiac remodeling [13,14]. TGF-β1 is a
potential target for anti-ﬁbrotic therapies. However, its multiple patho-
physiological actions render its therapeutic use impractical.
TGF-β1 activates two different membrane receptors, TGF-β1 type I
and type II, leading to serine phosphorylation of SMAD2/3. Phosphory-
lated SMADs form a heterotrimeric complex with SMAD4 and translo-
cate into the nucleus to promote speciﬁc gene transcription [15–17].
SMADs require heterodimerization with other transcription factors,
such as CBP and AP-1 [18,19]. Recently, it has been shown that FoxO
family members and the TGF-β1 signaling pathway act together to pro-
mote gene expression of many targets, such as inhibitors of cyclin/CDK
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connective tissue growth factor (CTGF) which is a main regulator of
extracellular matrix protein [20,21].
FoxO1 is a transcription factor involved in apoptosis, oxidative
stress, and cell differentiation [22,23]. FoxO1 is also regulated by
post-transcriptional modiﬁcations such as phosphorylation and
ubiquitination that control its stability and activity. Phosphorylation of
FoxO1 in serine and threonine residues leads to its inactivation and deg-
radation [24]. FoxO1 dephosphorylation by PP2A increases its activity,
promoting nuclear translocation, which induces gene transcription
[25], whereas TGF-β1 increases PP2A activity [26]. However, whether
TGF-β1 regulates FoxO1 expression or transcriptional activity in CF is
unknown.
FoxO1 has shown to be an important cell cycle regulator [27,28],
through p21waf/cip regulation [20,21,29]. In addition, p21waf/cip is
also required for CF differentiation into CMF [30]. CTGF is another pro-
tein involved in CF differentiation that is transcriptionally regulated by
TGF-β1 and FoxO1 [20,31,32].
Based on this evidence, we hypothesized that TGF-β1 regulates CF
differentiation through a mechanism involving FoxO1 regulation.
2. Material and methods
2.1. Materials
TGF-β1 and Accutase® were obtained from Millipore. 488 Alexa
Fluor® conjugated secondary antibodies, actinomycin D, cyclohexi-
mide, MG132, Bradford solution, propidium iodide, and primary an-
tibodies (GAPDH, β-tubulin, α-SMA) were obtained from Sigma-
Aldrich. Primary antibodies (FoxO1 and p-FoxO1) were obtained
from Cell Signaling Technologies. Primary antibodies (p21waf/cip,
lamin A/C, pro-collagen I, and CTGF) were obtained from Abcam.
Secondary antibodies conjugated with horseradish peroxidase
were obtained from Calbiochem. Collagen rat tail solution, RNAse,
Trypan blue, lipofectamine, Opti-MEM®, and siRNAs were obtained
from Life Technologies. All adenoviruses used in this work were a
kind gift from Dr. Joseph A Hill, University of Texas, Southwestern
Medical Center (Dallas, Texas). ECL Advance Western blotting
Detection Kit was obtained from GE Healthcare Europe GmbH.
2.2. Cell culture and treatments
CFs were isolated from the left ventricle (LV) of 3-day-old Sprague–
Dawley rats. Brieﬂy, LVs were harvested, cut into small pieces (~1–
2 mm), and placed in a Petri dish. A total of 10 mL Dulbecco's modiﬁed
Eagle'smedium containing 10% fetal bovine serum (FBS) and antibiotics
were added to Petri dishes. Petri dishes weremaintained at 37 °C under
5% CO2 in a humidiﬁed incubator until reaching 70% conﬂuence. Adher-
ent cells were cultivated. Cells from passage 1 were used for all experi-
ments. Cells were maintained in M199 medium for 18 h. CFs were
stimulated with TGF-β1 (1–10 μg/mL) for different experimental
times (2 to 72 h). For the inhibition experiments, cells were incubated
with actinomycin D (transcription inhibitor, 2 μg/mL), cycloheximide
(translation inhibitor, 1 μM), and MG132 (proteasome inhibitor,
10 nM) for 1 h before TGF-β1 incubation.
2.3. Western blot analysis
After respective treatments, cells were lysed in 50mMTris, 300mM
NaCl, 1 mMMgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 20% glycerol, 1% NP40,
0.5mMDTT, and inhibitor cocktail. Lysateswere vigorously vortexed for
10 s and centrifuged at 15,000 rpm for 10min, and total protein content
was determined using Bradford assay. Equivalent amounts of protein
were subjected to SDS-PAGE.Western blottingwas performed by trans-
ferring proteins to nitrocellulosemembranes and blockingwith 10% fat-
free milk (w/v) in TBS-tween for 1 h at room temperature. Membraneswere probed with the appropriate primary antibody overnight at 4 °C
and then with peroxidase-conjugated secondary antibody for 2 h at
room temperature. Finally, the ECL AdvanceWestern blotting Detection
Kit was used for immunodetection. Protein levels were determined by
densitometric analysis using Image J (NIH, Bethesda, MD, USA) and
normalized to the corresponding GAPDH level.
2.4. Immunoﬂuorescence assay
CFs were ﬁxed in 4% paraformaldehyde solution for 20 min at room
temperature and permeabilized in 0.1% Triton X100 for 10 min at room
temperature. Non-speciﬁc proteinswere blockedwith 3% bovine serum
albumin solution for 30 min at room temperature. Cells in coverslips
were incubated with the appropriate primary antibody overnight at 4
°C and an appropriate ﬂuorophore-conjugated secondary antibody for
2 h at room temperature. Images were obtained using a spinning-disk
microscope.
2.5. Subcellular fractionation
Cells were lysed in 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, and 0.05% NP40 (pH 7.9), kept on ice for 10 min, and
centrifuged at 300 rpm for 10 min at 4 °C. Supernatants corresponded
to cytosol samples. Pellets were resuspended in 5 mM HEPES, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 26% glycerol (v/v) (pH 7.9).
NaClwas added to obtain a300mMNaClﬁnal concentration; themixture
was maintained on ice for 30 min and then centrifuged at 24,000 g for
20 min at 4 °C. Pellets were discarded, and supernatants corresponded
to nuclear extracts. Protein content was analyzed using Bradford assay.
The purity of the subcellular fractions was assessed using β-tubulin for
the cytosol and lamin A/C for the nucleus.
2.6. Cell proliferation
CF proliferation was induced with FBS at concentrations ranging
from 1% to 10% in M199medium for 24 h. To evaluate cell proliferation,
two techniques were used: i) Trypan blue assay: Cells were detached
from culture dishes with Accutase®. After detachment, 100% FBS was
added to ensure cell integrity and inhibit further Accutase® action.
Cell number was determined by the trypan blue exclusion method on
a Neubauer chamber. Cell count was performed in quadruplicate. ii)
Crystal violet assay: Cells were stainedwith 10% crystal violet in ethanol
for 20min at room temperature. Stained cells were then lysedwith 50%
ethanol. Crystal violet absorbance wasmeasured at 590 nM on amicro-
plate. A plot of crystal violet absorbance versus cell number (from
10,000 to 200,000 cells) was used to determine cell number in each
sample.
2.7. Cell cycle analysis
Trypsin-EDTA 1×-detached cells were centrifuged at 2000 rpm for
5min at 4 °C, resuspended in coldmethanol, and stored at−20 °C over-
night. Cell were centrifuged at 2000 rpm for 5min at 4 °C, and the pellet
was resuspended in PBS solution containing RNAse (1 μg/mL) and kept
at room temperature for 2 h. Cells were incubated with propidium
iodide solution (10 μg/mL) for 1 min at room temperature. Finally, cell
cycle was analyzed in a ﬂow cytometer (Becton Dickinson). Data were
expressed as % of cells in G0/G1 and S/G2/M.
2.8. FoxO1 and FoxO3a silencing
CFs were seeded in 35 mm dishes at 80% conﬂuence and serum-
deprived overnight. Lipofectamine+ Opti-MEM® (100 μL) and speciﬁc
siRNA + Opti-MEM® (100 μL) were prepared, incubated for 15 min at
room temperature, mixed, and then incubated for an additional
15 min. 800 μL of Opti-MEM was added and transferred to the cells.
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an additional 24 h. Scramble siRNA (Silencer® Negative Control) was
used as a control. The sequences used were: FoxO1: 5′ → 3′ (sense)
GCACCGACUUUAUGAGCAAtt; (antisense) UUGCUCAUAAAGUCGG
UGCtg. FoxO3a: 5′ → 3′ (sense) AGCUCUUGGUGGAUCAUCtt; (anti-
sense) UGAUGAUCCACCAAGAGCUct.Fig. 1. TGF-β1 increases FoxO1 andα-SMAprotein levels. A) CFs were incubated for 48 hwith T
were incubated with TGF-β1 (10 ng/mL) for 0 to 72 h. D) CFs were preincubated with actinom
were then incubated with TGF-β1 (10 ng/mL) for 24 h. In A), B), and D), FoxO1 and α-SMA p
C), FoxO1 was detected by immunoﬂuorescence using anti-FoxO1 antibody and Alexa Fluor®
SMA antibody and Alexa Fluor® 566-conjugated secondary antibody (red staining). **p b 0.0
four independent experiments.2.9. Adenoviral transduction
CFs were plated at 70% conﬂuence and serum-deprived overnight.
Three different adenoviruses were used, wild-type FoxO1 (Ad-FoxO1-
wt), constitutively active FoxO1 (Ad-FoxO1-ca), and adenovirus green
ﬂuorescent protein (Ad-GFP) as a control. Adenoviruses were added atGF-β1 (0 to 20 ng/mL). B) CFswere incubatedwith TGF-β1 (10 ng/mL) for 0 to 72 h. C) CFs
ycin D (ACT, 2 μg/mL), cycloheximide (CHX, 10 μM), or MG132 (MG, 10 nM) for 1 h; cells
rotein levels were quantiﬁed by Western blotting. GAPDH was used as a load control. In
488-conjugated secondary antibody (green staining). α-SMA was detected using anti-α-
1 and ***p b 0.001 vs. control (C); ##p b 0.01 vs. TGF-β1 (−). Data are mean ± SEM of
Fig. 2. TGF-β1 promotes FoxO1 activity. A) CFs were incubatedwith TGF-β1 (10 ng/mL) for 0 to 8 h. p-FoxO1 and FoxO1 protein levels were determined byWestern blotting. GAPDHwas
used as a load control. In B), CFs were seeded on coverslips and then stimulated with TGF-β1 (10 ng/mL) for 2, 4, and 8 h. Nuclear localization of FoxO1was detected by immunoﬂuores-
cence using anti-FoxO1 antibody and Alexa Fluor® 488-conjugated secondary antibody (green staining). α-SMA was detected using anti-α-SMA antibody and Alexa Fluor® 566-
conjugated secondary antibody (red staining). C) CFs were stimulatedwith TGF-β1 (10 ng/mL) for 4 and 8 h. FoxO1 protein levels in nuclei were determined byWestern blotting. Nuclear
isolation was performed by centrifugation as mentioned in the Material and methods section. FoxO1 cytosolic protein levels were determined from the ratio of FoxO1 to β-tubulin, and
nuclear FoxO1 content was determined from the ratio of FoxO1 to lamin A/C, both reported as -fold over control. D) and E) CF were incubated with TGF-β1 (10 ng/mL) for different
experimental times (0 to 72 h). SOD2 (D) and p21waf/cip (E) protein levels were determined by Western blotting. GAPDH was used as a load control. *p b 0.01 **p b 0.01 and
***p b 0.001 vs. control (C); #p b 0.01 and ###p b 0.001 vs. control nuclear (C). Data are mean ± SEM of four independent experiments.
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100 was chosen to realize our experiments because it showed no loss
of cell viability (measured by cell count and amount of protein) and
this concentration induced FoxO1 overexpression greater than MOI 50.
2.10. Collagen gel contraction assay
Twenty-four well dishes were coated with 3% BSA solution over-
night. In each well, 400 μL of collagen gel solution (1 mg/mL in PBS)
and 100 μL of cell suspension (50,000 cells per well) were added, gently
homogenized, andmaintained at 37 °C for 2 h. Gels were detached from
the edge of thewell with a sterile pipette tip, and 500 μL of M199medi-
um was added. Gel contraction was determined after 48 h and
expressed as the ratio between the initial and the ﬁnal area of collagen
gel.
2.11. Cell adhesion assay
After different assays, the CFs were trypsinized, counted and seeded
(1 × 105 cell/well) into 12-well plate. The plate wasmaintained at 37 °C
for 1 h. Then the adherent cells were then ﬁxed with 4% paraformalde-
hyde for 15 min at room temperature. Fixed CFs were washed with PBS
and stained with crystal violet (0.5% w/v crystal violet in 20% ethanol)
for 10 min. Plates were washed with water and allowed to dry
completely. Finally, 2% SDS was added for 30 min at room temperature,
to solubilize the ﬁxed and stained cells and the absorbance was read at
550 μm.
2.12. Statistical analysis
Data are presented as mean ± SEM from at least four independent
experiments. Statistical analysis was performed using one-way
ANOVA and Tukey's test for multiple comparisons with GraphPad
Prism 5.0 software. p b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. TGF-β1 increases FoxO1 protein levels
Treating CF with TGF-β1 for 24 h increased FoxO1 and α-SMA pro-
tein levels in a dose-dependent manner, with signiﬁcant effects from
5 ng/mL (Fig. 1A). Furthermore, TGF-β1 also increased FoxO1 and α-
SMA protein levels in a time-dependentmanner, with signiﬁcant effects
from 24 h (Fig. 1B). Similar results were obtained with immunoﬂuores-
cence, thus the treatment with TGF-β1 for 48 h increased FoxO1 and in
addition, the increased of levels and cytoskeleton incorporation of α-
SMA (Fig. 1C). To assess the mechanism involved in the increased
FoxO1 levels induced by TGF-β1, CFs were pretreated with actinomycin
D (gene transcription inhibitor), cycloheximide (protein translation in-
hibitor), and MG132 (proteasome inhibitor). Actinomycin D and cyclo-
heximide abolished the TGF-β1-induced FoxO1 protein level increase,
whereas MG132 had no effect (Fig. 1D). These results show that TGF-
β1 increases FoxO1 gene transcription and translation.
3.2. TGF-β1 increases FoxO1 activity
Phosphorylation at serine 256 promotes FoxO1 inactivation and
degradation. TGF-β1 induced FoxO1 dephosphorylation in a time-
dependent manner (Fig. 2A). In parallel to FoxO1 dephosphorylation,
TGF-β1 induced an increase in FoxO1 nuclear localization as assessedFig. 3. FoxO1 knockdown decreases the effects of TGF-β1 in cardiac ﬁbroblasts. CFs were transf
(Scr) for 16 h and then stimulated with TGF-β1 (10 ng/mL) for 48 h. (A) FoxO1 protein levels w
contentwas quantiﬁed by Bradford assay.α-SMAwas evaluated byWestern blotting (C) and im
Western blotting. GAPDH was used as a load control. (G) CF contractile ability was evaluated
contraction, and the bar graph shows the percentage of gel area reduction as compared to t
#p b 0.05, ##p b 0.01 and ###p b 0.001 vs. Scr + TGF-β1. Data are mean ± SEM of four indepenby immunoﬂuorescence (Fig. 2B). This result was corroborated by sub-
cellular fractionation. TGF-β1 treatment increased FoxO1 levels in the
nucleus while decreasing its content in the cytosol (Fig. 2C). In order
to verify that FoxO1 dephosphorylation and nuclear translocation
were associated with increased transcriptional activity, two FoxO1-
regulated genes, antioxidant enzyme SOD2 and cell cycle regulator
p21waf/cip, were analyzed. TGF-β1 increased both SOD2 (Fig. 2D) and
p21waf/cip (Fig. 2E) protein levels in a time-dependent manner.
Taken together, these results suggest that TGF-β1 promotes FoxO1 tran-
scriptional activity.
3.3. FoxO1 is involved in the TGF-β1-induced differentiation of cardiac
ﬁbroblasts into myoﬁbroblasts
TGF-β1 promotes CF differentiation. TGF-β1 induced differentiation
of CF into CMF, as visualized by increases in total protein content, α-
SMA, pro-collagen I, CTGF, p-SMAD3, YB-1, collagen gel contractile
ability, and cell adhesion (Suppl. Figs. 1–2).
FoxO1's participation in TGF-β1-induced CF differentiationwas eval-
uated using FoxO1 siRNA (si-FoxO1). si-FoxO1 reduced FoxO1 but not
FoxO3 protein levels, while siRNA for FoxO3 reduced FoxO3 but not
FoxO1 protein levels (Suppl. Fig. 3). FoxO1 knockdown prevented the
TGF-β1-dependent increase in FoxO1 protein levels. This effect was
speciﬁc to si-FoxO1, because siRNA for FoxO3 did not reproduce the
effect (Fig. 3A). Moreover, siRNA for FoxO1 also abolished the TGF-β1-
dependent increases in total protein content, α-SMA, pro-collagen I,
CTGF protein levels and assembly of α-SMA on stress ﬁbers (Fig. 3B–
F). Furthermore, FoxO1 knockdown prevented TGF-β1-dependent
collagen gel contraction (Fig. 3G). On the contrary, the cell adhesion,
SMAD3 activity, and YB-1 protein level increases promoted by TGF-β1
were not affected by FoxO1 silencing (Suppl. Fig. 4). These results
suggest that FoxO1 is involved in TGF-β1-dependent differentiation of
CF into CMF.
3.4. FoxO1 is involved in the cytostatic effects of TGF-β1 in cardiac
ﬁbroblasts
The cytostatic effect of TGF-β1 was evidenced by the prevention of
FBS-induced CF proliferation and cell cycle arrest (Suppl. Figs. 5–6).
FoxO1 knockdown abolished the TGF-β1-dependent inhibition of CF
proliferation induced by FBS (Fig. 4A and Suppl. Fig. 6). The same effect
was observed when cell cycle was analyzed. FBS decreased the number
of cells in G0/G1while increasing the number of cells in S/G2/M. TGF-β1
completely abolished the FBS-induced effects on cell cycle. However,
pretreatment with siRNA for FoxO1 completely prevented the effects
of TGF-β1 (Fig. 4B) (the representative histograms of this assays is
showed in Suppl. Fig. 7). These effects could be associated with the
control of cyclins, because FoxO1 knockdown abolished the TGF-β1-
dependent increase in p21waf/cip (Fig. 4C). These results show that
FoxO1 is involved in the cytostatic effect of TGF-β1 on CF, probably
through the control of p21waf/cip.
3.5. FoxO1 overexpression enhances the effects of TGF-β1 in cardiac
ﬁbroblasts
We demonstrated that TGF-β1 controls FoxO1 expression and that
FoxO1 knockdownprevented the effects of TGF-β1 in CF. In order to ver-
ify the participation of FoxO1 in the TGF-β1-dependent differentiation
of CF into CMF, we overexpressed a wild-type (Ad-FoxO1-wt) and a
constitutive active form (Ad-FoxO1-ca) of FoxO1 with adenovirusesected with FoxO1 siRNA (si-FoxO1), FoxO3a siRNA (si-FoxO3a), or siRNA negative control
ere determined byWestern blotting. GAPDHwas used as a load control. (B) Total protein
munoﬂuorescence (D). Pro-collagen I (E), and CTGF (F) protein levelswere determined by
by collagen gel contraction assay. The panel shows representatives images of collagen gel
he initial area. The ﬁnal area was evaluated at 48 h. **p b 0.01 and ***p b 0.001 vs. Scr;
dent experiments.
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Fig. 4. FoxO1 knockdown decreases the cytostatic effects of TGF-β1 on cardiac ﬁbroblasts. CFs were transfected with si-FoxO1, si-FoxO3a, or Scr for 16 h and then stimulatedwith TGF-β1
(10 ng/mL) for 48 h and incubatedwith FBS 10% for 24h. A) Cell proliferationwas evaluated by cell count in a Neubauer chamber. B) CF distribution inG0/G1 phase and S/G2/Mphasewas
evaluated byﬂowcytometry. (C) p21waf/cip protein levelswere determinedbyWestern blotting. GAPDHwas used as a load control. *p b 0.05, **p b 0.01 and ***p b 0.001 vs. Scr; #p b 0.05,
##p b 0.01 and ###p b 0.001 vs. Scr + FBS; &p b 0.05 vs. Scr + FBS + TGF-β1. Data are mean ± SEM of four independent experiments.
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wasused as a transduction control. CF transduced for 24 hwith both Ad-
FoxO1-wt and Ad-FoxO1-ca showed increased FoxO1 protein levels
(Suppl. Fig. 8). The increases in total protein content, α-SMA, pro-
collagen I, CTGF protein levels and assembly ofα-SMA on stress ﬁber in-
duced by TGF-β1 were potentiated by both FoxO1-wt and FoxO1-ca
overexpression (Fig. 5A–E). As expected, both FoxO1-wt and FoxO1-ca
enhanced TGF-β1-induced collagen gel contraction (Fig. 5F). On the
contrary, the CF adhesion, SMAD3 activity, and YB-1 protein level in-
creases induced by TGF-β1 were not affected by FoxO1 overexpression
(Suppl. Fig. 4). These results show that FoxO1 is involved in
differentiation of CF to CMF.3.6. FoxO1 overexpression enhances the cytostatic effects of TGF-β1 in
cardiac ﬁbroblasts
TGF-β1 inhibited the CF proliferation induced by FBS. FoxO1-wt and
FoxO1-ca overexpression enhanced the cytostatic effect of TGF-β1
(Fig. 6A and Suppl. Fig. 6). The same result was observed when cell
cycle was assessed. FBS decreased the CF population in G0/G1 while in-
creasing thepopulation in S/G2/M. FoxO1-wt and FoxO1-ca overexpres-
sion enhanced the effect of TGF-β1 as indicated by a further increase in
CF population in G0/G1 and a further decrease in S/G2/M (Fig. 6B) (the
representative histograms of this assays is showed in Suppl. Fig. 7).
FoxO1 promotes the expression of cell cycle regulator p21waf/cip,
which induces cell cycle arrest and decreases cell proliferation. TGF-β1
increased p21waf/cip protein levels at 48 h, whereas FoxO1-wt and
FoxO1-ca overexpression further increased p21waf/cip protein levels
(Fig. 6C). Taken together, these results show that FoxO1 overexpression
enhances the cytostatic effects of TGF-β1.4. Discussion
The data presented in this paper show that FoxO1 is a key regulator
of the effects of TGF-β1 on differentiation of CF into CMF. FoxO1
regulates the expression of several differentiation markers (α-SMA,
pro-collagen I, CTGF, and p21waf/cip) and controls both CF proliferation
and collagen gel contraction.
Our results show that TGF-β1 regulates FoxO1 expression. Similarly,
TGF-β1 increases FoxO1 expression in primary chondrocyte cultures,
which correlates with ﬁbrosis and cellular aging [33]. Moreover,
FoxO1 induces increased TGF-β1 expression in skin wound healing
[34]. However, regulation of FoxO1 expression by TGF-β1 seems to be
cell type-dependent; in mesenchymal cells such as chondrocytes or ﬁ-
broblasts, or epithelial cells such as keratinocytes [20], TGF-β1 induces
FoxO1 expression, whereas in malignant cells, TGF-β1 inhibits FoxO1
expression [35].
TGF-β1 regulates FoxO1 expression in CF, demonstrated using
actinomycin D and cycloheximide. In rat hepatocytes, fasting activates
the histone acetyltransferase p300 to induce FoxO1 expression. p300
recognizes a speciﬁc promoter site in FoxO1 and promotes its gene tran-
scription and protein translation [36,37]. Interestingly, TGF-β1 activates
and increases the expression of p300, which is associated with collagen
induction [38,39], suggesting that TGF-β1 could promote FoxO1 tran-
scription by activating p300.
FoxO1 undergoes post-translational modiﬁcations that regulate its
nuclear localization, where it exerts its transcriptional activity [40].
FoxO1 phosphorylation controls its transcriptional activity and stability
[41]. In fact, AKT activation induced by insulin promotes FoxO1 phos-
phorylation at Ser256, which favors its cytosolic localization, decreases
its transcriptional activity, and promotes FoxO1 degradation [42]. In
contrast, oxidative stress, fasting, and insulin resistance decrease
Fig. 5. FoxO1 up-regulation enhances the effects of TGF-β1 on cardiac ﬁbroblasts. CFs were transducedwith either FoxO1-wild-type adenovirus (Ad-FoxO1-wt), FoxO1 constitutive active
adenovirus (Ad-FoxO1-ca), or GFP adenovirus (Ad-GFP) for 24 h and then stimulated with TGF-β1 (10 ng/mL) for 48 h. A) Total protein amount was analyzed by Bradford assay.α-SMA
was evaluated by Western blotting (B) and immunoﬂuorescence (C). Pro-collagen I (D), and CTGF (E) protein levels were determined by Western blotting. GAPDH was used as a load
control. (F) CF contractile ability was evaluated by collagen gel contraction assay. The panel shows representatives images of collagen gel contraction, and the bar graph shows the
percentage of gel area reduction as compared to the initial gel area. The ﬁnal area was evaluated at 48 h. **p b 0.01 and ***p b 0.001 vs. GFP; #p b 0.05 and ##p b 0.01 vs. GFP + TGF-
β1. Data are mean ± SEM of four independent experiments.
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scriptional activity [43–45]. Our results demonstrate that in CF, TGF-β1
decreases FoxO1 phosphorylation and increases FoxO1 nuclear localiza-
tion. The phosphatases involved in FoxO1 dephosphorylation are yet to
be conclusively identiﬁed. However, PP2A appears to be themain phos-
phatase involved in this process [25]. Hepatocyte-speciﬁc ablation of
PP2A attenuates progression of liver ﬁbrosis via TGF-β1/SMAD signaling
[26], which indicates a possible relationship between TGF-β1 and PP2A.
This evidence suggests that TGF-β1 activates PP2A to induce FoxO1 de-
phosphorylation, promoting expression of SOD2 and p21waf/cip, two
speciﬁc FoxO1 gene targets. Furthermore, the p21waf/cip promoterhas several recognition sequences, including FoxO (FHBE) and SMAD
(SBE) element response [46], suggesting that both proteins are required
for p21waf/cip expression. In fact, our results indicate that FoxO1down-
regulation decreased p21waf/cip expression induced by TGF-β1. These
data suggest that TGF-β1 induces FoxO1 activity in CF.
CF differentiation induced by TGF-β1 is related to the expression of
many proteins associated with ﬁbrosis, such as collagen I (the main
MEC protein) [47], CTFG (a major TGF-β1 signaling effector) [48], and
α-SMA (the main CMF marker) [49]. In skin ﬁbroblasts, ultraviolet
light induces FoxO1 activation and increases collagen I, whereas
FoxO1 down-regulation decreases this effect [47]. Furthermore, in
Fig. 6. FoxO1 up-regulation enhances the cytostatic effects of TGF-β1 on cardiac ﬁbroblasts. CFs were transducedwith Ad-FoxO1-wt, Ad-FoxO1-ca, or Ad-GFP for 24 h and then stimulated
with TGF-β1 (10 ng/mL) for 48 h. CFswere then incubatedwith FBS 10% for 24h. A) Cell proliferationwas evaluated by cell count in aNeubauer chamber. B) CF distribution inG0/G1phase
and S/G2/Mphasewas evaluated by ﬂow cytometry. (C) p21waf/cip protein levelswere determined byWestern blotting. GAPDHwas used as a load control. **p b 0.01 and ***p b 0.001 vs.
GFP; #p b 0.05, ##p b 0.01 and ###p b 0.001 vs. GFP + FBS; &p b 0.05 vs. GFP + FBS + TGF-β1. Data are mean ± SEM of four independent experiments.
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primary keratinocytes, FoxO1 is necessary for TGF-β1-induced CTGF ex-
pression [20]. There is no evidence indicating that α-SMA is regulated
by FoxO1. Our results show that FoxO1 up-regulation enhanced the ef-
fects of TGF-β1 onpro-collagen I, CTGF, andα-SMA expression,whereas
FoxO1 knockdown inhibited the effects of TGF-β1 on differentiation
markers, suggesting that FoxO1 is necessary for the CF differentiation
induced by TGF-β1.
Themechanismbywhich FoxO1 regulates the effects of TGF-β1 in CF
is unknown. SMAD3 activity and YB-1 protein levels are regulated by
TGF-β1; both proteins are important in TGF-β1-induced differentiation
in the epithelial-mesenchymal transition [49–51]. However, our results
indicate that although TGF-β1 increased both SMAD3 activity and YB-1
expression, these effects were not controlled by FoxO1. These data sug-
gest that FoxO1 likely regulates the effects of TGF-β1 by a different
mechanism. SMAD7 and c-Ski are other important proteins that regu-
late cardiac ﬁbroblast differentiation induced by TGF-β1 [52,53]. It
would be interesting to analyzewhether FoxO1 regulates these proteins
and whether such regulation could control the effects of TGF-β1 in CF.
Cell differentiation generally leads to decreased cell proliferative ca-
pacity, as is the case for cardiomyocytes [54]. The evidence regarding
the proliferative effects of TGF-β1 on CF differentiation is controversial.
Drissen et al. showed that TGF-β1 triggers CF differentiation and de-
creased cell proliferation [55], whereas other authors indicated that
TGF-promotes proliferation and differentiation of CF [56]. Moreover,
our results show that TGF-β1 inhibited CF proliferation induced by
FBS. However, in human kidney ﬁbroblasts, TGF-β1 induced cell prolif-
eration through a FGF2-dependent mechanism [57]. These data suggest
that the effects of TGF-β1 on ﬁbroblast proliferation depend on both
organ and species. Our results indicate that the antiproliferative effectof TGF-β1 was enhanced by FoxO1 overexpression and decreased by
FoxO1 knockdown, suggesting that FoxO1 is essential to the decrease
in TGF-β1 induced CF proliferation. FoxO family proteins induce the ex-
pression of several proteins involved in cell cycle control, such as
p15ink, p27kip, and p21waf/cip. These proteins are cyclin/CDK complex
inhibitors that induce cell cycle arrest and decrease cell proliferation
[58]. In mesenchymal cells, dexamethasone via the glucocorticoid
receptor inhibits cell proliferation through increased p21waf/cip
expression [59]. In addition, p21waf/cip is a key element in the CF
differentiation to CMF induced by TGF-β1 [30]. Our data suggest
that FoxO1 is important in the increased p21waf/cip expression
induced by TGF-β1 and inhibition of CF proliferation.
An important function of the CF is its ability to contract the extracel-
lular matrix (ECM), which plays a role in healing damaged tissue. TGF-
β1 enhances the contractile ability of CF [60]. In addition, TGF-β1 is
important in cardiac tissue healing after deleterious events such as
myocardial infarction [61,62]. Our results show that FoxO1 in necessary
for the collagen contraction induced by TGF-β1. There is no direct
evidence linking FoxO1 to the contractile ability of CF or to their role
in cardiac healing. However, it has been reported that FoxO1 promotes
skin wound healing in hyperglycemic rats, while diabetic rats exhibit
decreased FoxO1 activity [40,63]. Our data would imply that TGF-β1
could promote cardiac tissue healing through FoxO1 regulation.
Finally, abundant data show that many molecules with demonstra-
ble anti-ﬁbrotic effects increase cAMP/PKA activity, including prostacy-
clin and natriuretic peptides [64,65]. In CF, cAMP elevations induced by
isoproterenol (ISO) and forskolin (FSK) inhibit TGF-β1-induced colla-
gen I andα-SMA expression [27]. Furthermore, the cAMP/PKA signaling
pathway promotes FoxO1 phosphorylation and induces its degradation
and inactivation [66,67]. This evidence suggests that ISO and FSK
137R. Vivar et al. / Biochimica et Biophysica Acta 1863 (2016) 128–138increase the cAMP-inhibiting CF differentiation induced by TGF-β1, by a
mechanism related to PKA activation and FoxO1 degradation. Taken to-
gether, the data from the literature and our experimental results
suggest that TGF-β1 regulates FoxO1 activity and expression, which is
crucial to the process of TGF-β1-induced CF differentiation to CMF.
4.1. Limitations
While most heart diseases occur in adults, we used neonatal rat CF,
only as a model to explain our ﬁndings to explain the mechanism why
Foxo1 regulates CF to CMF differentiation. In our laboratory, there is
considerable evidence that the phenomena that occur in the neonate
can be extrapolated to adults, just change the magnitude of the effects.
Finally, the main limitation of this study was that our studies were
conducted in vitro. Undoubtedly, our in vitro ﬁndings would have had
greater signiﬁcance if they had conducted similar assays in vivo; howev-
er, in these assays we cannot determine the participation of FoxO1 in
the differentiation of CF to CMF.
5. Conclusion
TGF-β1 increases FoxO1 transcriptional activity and expression.
FoxO1 is required for the antiproliferative effects of TGF-β1 and for
TGF-β1-induced promotion of CF differentiation, favoring the cellular
function associated to cardiac ﬁbrosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.10.019.
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